SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa.

SparingVision is a spin-off of Vision Institute (Institut de la Vision, Paris) whose purpose is to transfer into clinic phase an innovative therapeutic strategy regarding retinitis pigmentosa, the most frequent inherited retinal degeneration.
This genetical pathology of retina which turns to blindness has no cure at that day. This rare and orphan disease affects 40 000 patients in France and more than 1,5 million in the world.